BRAINSTORM CELL THERAPUTC
BCLI
BCLI was delisted on the 17th of July, 2025.
39 hedge funds and large institutions have $9.38M invested in BRAINSTORM CELL THERAPUTC in 2018 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 14 increasing their positions, 2 reducing their positions, and 4 closing their positions.
600% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 2
125% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 4
77% more capital invested
Capital invested by funds: $5.29M → $9.38M (+$4.1M)
15% more funds holding
Funds holding: 34 → 39 (+5)
0.21% more ownership
Funds ownership: 0.59% → 0.8% (+0.21%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$3.56M |
| 2 |
JP Morgan Chase
New York
|
+$510K |
| 3 |
Renaissance Technologies
New York
|
+$103K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$76.7K |
| 5 |
CPP
Crow Point Partners
Boston,
Massachusetts
|
+$71.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$1.26M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$94K |
| 3 |
Bank of New York Mellon
New York
|
-$15.1K |
| 4 |
SPIA
Steward Partners Investment Advisory
New York
|
-$9K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$5K |
BCLI Hedge Fund Activity: Q2 2018 in Review
39 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in BRAINSTORM CELL THERAPUTC (BCLI) for Q2 2018, worth a combined $9.38M — up 77% from $5.29M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new BCLI positions and 4 closed out — a net gain of 5 holders — while 14 added to existing stakes and 2 trimmed.
The largest buyer was Sabby Management, adding an estimated $3.56M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $1.26M sold.
- 39 institutional investors held BRAINSTORM CELL THERAPUTC (BCLI) as of Q2 2018, up from 34 in Q1 2018.
- Funds reported $9.38M of BRAINSTORM CELL THERAPUTC stock for Q2 2018, up 77% quarter-over-quarter.
- 9 funds opened new BRAINSTORM CELL THERAPUTC positions in Q2 2018 and 4 closed out, a net change of +5 holders.
- The largest BRAINSTORM CELL THERAPUTC buyer in Q2 2018 was Sabby Management, an estimated $3.56M added.
- The largest BRAINSTORM CELL THERAPUTC seller in Q2 2018 was Perceptive Advisors, an estimated $1.26M sold.
Based on aggregated 13F filings for Q2 2018.